This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Biphasic insulin

Authoring team

The biphasic insulins are mixed to combine the action profiles of the component soluble and isophane insulins. For example, Human Mistard 30is composed of 30% soluble and 70% isophane insulin.

Biphasic insulins are a mixture of a short- or rapid-acting insulin with an intermediate-acting insulin. These preparations can be used to cover mealtime and basal insulin requirements, and are often used twice a day (2)

There are also insulin analogue biphasic insulins

  • pre-mixed (biphasic) formulation of 30% insulin aspart and 70% protamine-crystallised insulin aspart is licensed as NovoMix 30 for the treatment of patients with diabetes
  • Humalog Mix25 and Humalog Mix50, consists of a mixture of 25% or 50% insulin lispro and 75% or 50% of a protamine suspension of insulin lispro, respectively
  • note that once insulin aspart or insulin lispro are co-crystallised with protamine, their absorption is slowed to a rate similar to that of an intermediate-acting conventional insulin such as isophane insulin
  • a review notes that both biphasic insulin aspart and biphasic insulin lispro have similar effects on HbA1c levels and the incidence of hypoglycaemia as a comparable mixture of biphasic conventional human insulin, but reduce postprandial glucose concentrations more

Reference:

  1. Drug and Therapeutics Bulletin (2004); 42(10):77-80.
  2. MeReC Bulletin 2007;17(4).

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.